P. Rae

1.8k total citations · 1 hit paper
8 papers, 1.4k citations indexed

About

P. Rae is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, P. Rae has authored 8 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 5 papers in Genetics and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in P. Rae's work include Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Acute Lymphoblastic Leukemia research (4 papers). P. Rae is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Acute Lymphoblastic Leukemia research (4 papers). P. Rae collaborates with scholars based in United States, Germany and Switzerland. P. Rae's co-authors include Francis J. Giles, Margaret Dugan, Maher Albitar, Jörge E. Cortes, Hagop M. Kantarjian, Kapil N. Bhalla, Oliver G. Ottmann, Leila Alland, Barbara Waßmann and Andreas Hochhaus and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

P. Rae

8 papers receiving 1.3k citations

Hit Papers

Nilotinib in Imatinib-Resistant CML and Philadelphia Chro... 2006 2026 2012 2019 2006 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Rae United States 6 984 679 476 412 279 8 1.4k
Lydia Wunderle Germany 9 1.2k 1.2× 739 1.1× 538 1.1× 193 0.5× 262 0.9× 17 1.5k
P. Le Coutre Germany 5 1.3k 1.4× 1.1k 1.6× 673 1.4× 143 0.3× 245 0.9× 5 1.6k
Phuong Dang Australia 12 1.4k 1.4× 1.1k 1.7× 643 1.4× 178 0.4× 334 1.2× 31 1.6k
Kara Johnson United States 15 607 0.6× 472 0.7× 337 0.7× 313 0.8× 114 0.4× 19 978
Matteo Molica Italy 16 487 0.5× 341 0.5× 113 0.2× 253 0.6× 163 0.6× 70 773
Devendra Hiwase Australia 20 944 1.0× 489 0.7× 174 0.4× 378 0.9× 296 1.1× 107 1.3k
Chetasi Talati United States 16 592 0.6× 326 0.5× 68 0.1× 512 1.2× 247 0.9× 78 1.1k
M Beran United States 14 407 0.4× 302 0.4× 113 0.2× 335 0.8× 209 0.7× 18 812
Kevin Yee United States 9 499 0.5× 267 0.4× 43 0.1× 480 1.2× 303 1.1× 12 1.2k
Naresh Punwani United States 12 268 0.3× 288 0.4× 230 0.5× 178 0.4× 241 0.9× 17 803

Countries citing papers authored by P. Rae

Since Specialization
Citations

This map shows the geographic impact of P. Rae's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Rae with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Rae more than expected).

Fields of papers citing papers by P. Rae

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Rae. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Rae. The network helps show where P. Rae may publish in the future.

Co-authorship network of co-authors of P. Rae

This figure shows the co-authorship network connecting the top 25 collaborators of P. Rae. A scholar is included among the top collaborators of P. Rae based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Rae. P. Rae is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Singer, Jonathan B., Yaping Shou, Francis J. Giles, et al.. (2007). UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. 21(11). 2311–2315. 91 indexed citations
2.
Kantarjian, Hagop M., Francis J. Giles, Lydia Wunderle, et al.. (2006). Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL. New England Journal of Medicine. 354(24). 2542–2551. 970 indexed citations breakdown →
3.
Giles, Francis J., Thomas Fischer, Jörge E. Cortes, et al.. (2006). A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies. Clinical Cancer Research. 12(15). 4628–4635. 264 indexed citations
5.
Ottmann, Oliver G., Frank Giles, Barbara Waßmann, et al.. (2005). Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant bcr-abl positive lymphoid malignancies. Journal of Clinical Oncology. 23(16_suppl). 3015–3015. 7 indexed citations
7.
Giles, Francis J., Thomas Fischer, Jörge E. Cortes, et al.. (2004). A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies.. Blood. 104(11). 1802–1802. 5 indexed citations
8.
Golemović, Mirna, Miloslav Beran, Francis J. Giles, et al.. (2004). AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.. Blood. 104(11). 2737–2737. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026